e-learning
resources
Vienna 2009
Monday, 14.09.2009
Exacerbations of COPD and bronchiectasis: aetiology and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Budesonide is not associated with increased risk of pneumonia in COPD patients
D. Sin, D. Tashkin, X. Zhang, F. Radner, U. Sjobring, A. Thoren, P. M. A. Calverley, S. Rennard (Vancouver, Canada; Los Angeles, Omaha, United States Of America; Lund, Sweden; Liverpool, United Kingdom)
Source:
Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment
Session:
Exacerbations of COPD and bronchiectasis: aetiology and treatment
Session type:
Thematic Poster Session
Number:
2352
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Sin, D. Tashkin, X. Zhang, F. Radner, U. Sjobring, A. Thoren, P. M. A. Calverley, S. Rennard (Vancouver, Canada; Los Angeles, Omaha, United States Of America; Lund, Sweden; Liverpool, United Kingdom). Budesonide is not associated with increased risk of pneumonia in COPD patients. Eur Respir J 2009; 34: Suppl. 53, 2352
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Is COPD pharmacotherapy associated with increased incidence of community-acquired pneumonia?
Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know?
Year: 2008
Increasing risk of exacerbation and mortality associated with increasing frequency and severity of exacerbations in COPD patients: EXACOS-UK
Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD
Year: 2021
Glitazones are associated with reduced risk of COPD exacerbations and mortality among patients with diabetes
Source: Annual Congress 2011 - COPD: burden of disease, imaging and management
Year: 2011
Six months azithromycin treatment in COPD patients with high risk of further exacerbations
Source: International Congress 2017 – Management of COPD
Year: 2017
β-blockers and risk of COPD exacerbation requiring hospitalisation in patients with COPD
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Factors associated with exacerbations in US patients with COPD
Source: Annual Congress 2009 - Exacerbations and characteristics of COPD
Year: 2009
The risk of hyperkalemia in COPD and asthma patients
Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases
Year: 2019
COPD patients with asthma, characteristics and risk of exacerbations
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
In hospitalized COPD exacerbation (COPDE) patients a 30-day readmission is associated with a progressive increased risk of mortality
Source: International Congress 2015 – COPD: interesting notes
Year: 2015
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010
Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD
Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity
Year: 2011
Osteoporosis risk associated with chronic corticoid inhalation therapy in patients with COPD
Source: Annual Congress 2009 - Prognosis and comorbidities in COPD
Year: 2009
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations
Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Year: 2019
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes
Source: International Congress 2018 – Disease exacerbations from a molecular point of view
Year: 2018
Patients at risk for COPD compared to patients diagnosed with COPD
Source: Annual Congress 2009 - Epidemiology of COPD
Year: 2009
Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying?
Source: Eur Respir J 2011; 37: 1-3
Year: 2011
The effect of smoking on exacerbation risk in eosinophilic patients with COPD
Source: Eur Respir J, 50 (6) 1702086; 10.1183/13993003.02086-2017
Year: 2017
The effect of smoking on exacerbation risk in eosinophilic patients with COPD
Source: Eur Respir J, 50 (6) 1701820; 10.1183/13993003.01820-2017
Year: 2017
Statin therapy and reduced risk of pneumonia in elderly patients with diabetes
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept